DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., today announces the signing of a manufacturing and supply agreement with QRxPharma, Inc., based in Bedminster, New Jersey, USA, for the production of their novel pain management product MoxDuo® capsules to supply the U.S. market through 2015.
The agreement covers the production of MoxDuo® Capsules, an immediate-release Dual Opioid® pain therapy comprised of a patented 3:2 fixed ratio combination of morphine and oxycodone, by DSM. DSM will supply commercial volumes upon marketing approval. DSM operates a 1.5 million square foot finished dosage facility in Greenville, North Carolina, USA, for oral solid dosage, as well as liquid steriles, and holds a range of regulatory approvals including the production of scheduled drugs.
Hans Engels, President, DSM Pharmaceuticals, Inc. stated: "We are honored to be working with QRxPharma for the supply of this product. Combining the expertise of QRx in developing innovative medicines with DSM's strength in Good Manufacturing Practices (GMP), enforced by the U.S. Food and Drug Administration , and supply chain management will provide a superior solution for patients."
QRxPharma, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders.
"We have had a very productive relationship with DSM over the years as we evolved MoxDuo® Capsules through to New Drug Application (NDA) filing, and we are now looking forward to launching our product into the acute pain marketplace in the US in 2012 with the manufacturing support of DSM," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.
No financial details are disclosed.